Raymond James cuts Cigna to Outperform on lack of near-term catalysts
Raymond James downgraded Cigna (CI) to Outperform from Strong Buy and cut its price target to $320 from $350, citing attractive valuation but fewer near-term catalysts. It pointed to moderating growth and PBM headwinds. The firm cited Q2 adjusted EPS of $7.78, raised 2026 guidance to at least $30.45, and modeled $30.50 (2026), $33.50 (2027), $37.00 (2028).
How this was made
The 30-second read
Why it matters
Traders may reprice near-term earnings risk for Cigna’s PBM segment, while longer-dated upside hinges on the assumed easing of PBM headwinds and continued buybacks.
Market read
A sell-side downgrade with a specific PT reduction and a clear near-term catalyst gap can drive short-term positioning, even as the note remains valuation-supportive.
What to watch
The article cites a strong Q2 with EPS beat and better medical loss ratio, plus modest 2026 guidance raise, which may reduce the practical impact of the downgrade.
Background
Raymond James moved Cigna from Strong Buy to Outperform, lowering the PT amid PBM transition headwinds and moderating growth.
Ticker impact
Raymond James downgraded Cigna to Outperform and cut its price target to $320, citing lack of near-term catalysts and PBM headwinds.
Near-term downside bias from the PT cut and catalyst framing, partially offset by the maintained positive valuation view.
This is a single-brokerage action with explicit PT and thesis (PBM transition headwinds, slower growth), plus management EPS guidance and valuation metrics that temper the bearishness.
Market effects
Reinforces sell-side caution on health insurer PBM transition execution and near-term earnings momentum.
Primarily US large-cap healthcare/managed care sentiment.
Limited direct global spillover; could influence broader managed-care risk appetite.
Counterpoint
The brokerage still calls valuation undemanding and expects 2027 earnings growth acceleration as PBM headwinds ease, which can limit downside follow-through.
Key entities
- companyCigna Group
Subject of the downgrade, PT cut, and PBM headwind thesis; also referenced with Q2 EPS beat and updated 2026 guidance.
- business_segmentEvernorth
Cigna segment cited as contributing to stronger-than-expected Q2 performance.
